Citadel Advisors’s Ensysce Biosciences ENSC Stock Holding History

Citadel Advisors’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25K	Buy	86,193 +28,830	+50%	+$10.4K	﹤0.01%	13353
2026 Q1	$30.9K	Buy	+57,363	New	+$36.4K	﹤0.01%	12563
2025 Q4	–	Sell	-14,518	Closed	-$34.4K	–	12983
2025 Q3	$34.4K	Buy	+14,518	New	+$31.2K	﹤0.01%	12354
2024 Q4	–	Sell	-1,574	Closed	-$5.67K	–	14716
2024 Q3	$5.67K	Sell	1,574 -4,182	-73%	-$25.4K	﹤0.01%	13469
2024 Q2	$43.7K	Buy	+5,756	New	+$52.5K	﹤0.01%	11913
2023 Q4	–	Sell	-1,274	Closed	-$26.2K	–	14502
2023 Q3	$26.2K	Buy	+1,274	New	+$36.2K	﹤0.01%	12394
2023 Q1	–	Sell	-235	Closed	-$31.7K	–	14892
2022 Q4	$31.7K	Buy	+235	New	+$112K	﹤0.01%	12670

Other funds holding ENSC

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

TIAM2

Tru Independence Asset Management 2 Portland, Oregon $185M AUM 20.3% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Citadel Advisors's ENSC Position: Q2 2026 in Review

Citadel Advisors increased its Ensysce Biosciences (ENSC) stake by 50% in Q2 2026, buying an estimated $10.4K and bringing the position to 86,193 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #13353.

Citadel Advisors first reported a position in ENSC in Q4 2022 and has held it in 7 quarters since. The position peaked at $43.7K in Q2 2024. 18 funds tracked by Wall St. Rank hold ENSC as of Q2 2026.

Citadel Advisors held 86,193 shares of Ensysce Biosciences worth $25K as of Q2 2026.
Citadel Advisors bought 28,830 Ensysce Biosciences shares in Q2 2026, an estimated $10.4K.
Ensysce Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13353 holding.
Citadel Advisors first reported a position in Ensysce Biosciences in Q4 2022 and has held it in 7 quarters since.
Citadel Advisors's Ensysce Biosciences position peaked at $43.7K in Q2 2024.
18 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.